Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective studyBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7360.365 (Published 17 August 2002) Cite this as: BMJ 2002;325:365
- Annelies Wilder-Smith, head ()a,
- Timothy M S Barkham, consultant microbiologistb,
- Arul Earnest, statisticianc,
- Nicholas I Paton, headd
- aTravellers' Health and Vaccination Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433
- bDepartment of Pathology and Laboratory Medicine, Tan Tock Seng Hospital
- cClinical Epidemiology Unit, Tan Tock Seng Hospital
- dDepartment of Infectious Diseases, Tan Tock Seng Hospital
- Correspondence to: A Wilder-Smith
- Accepted 13 March 2002
The annual Islamic pilgrimage to Mecca and Medina (Hajj) attracts more than two million pilgrims from all over the world. Overcrowding provides ideal conditions for transmission of meningococci.During the Hajj 2000 an international outbreak of meningococcal disease occurred.1 This outbreak generated particular interest as it was caused by serogroup W135, which hitherto had not played a major role in epidemics. 2 3 Furthermore, many close contacts of asymptomatic returning pilgrims were affected.2 Although vaccination can protect pilgrims against invasive disease due to W135, it does not prevent acquisition of pharyngealcarriage, which is the primary source for transmission.4 Returning pilgrims may spread the bacteria to their unvaccinated household contacts or even to the community at large. We investigated the extent of transmission of Neisseria meningitidis in Hajj pilgrims and their contacts, in order to provide evidence for developing a rationalpublic health policy.
Methods and results
We conducted a prospective study of meningococcal carriage in Singaporean pilgrims before the Hajj 2001 and in pilgrims and their household contacts two weeks after return from the Hajj. We performed serogrouping and pulsed field gel electrophoresis on meningococcal isolates to determine the predominant serogroup and relatedness of the strains. We questioned participants about the occurrence of any symptoms of upper respiratory tract infection, use of antibiotics within the past month, and number of people in the household.
We took tonsillopharyngeal swabs from 204 Malay pilgrims at the time of vaccination with quadrivalent meningococcal vaccine (median 39 (range 18-72) days before their departure for the Hajj pilgrimage). Median age was 48 (24-74) years, and 92 (45%) were men. Only one of these pilgrims carried N meningitidis, which was identified as serogroup X.
We took repeat swabs from 171 (84%) of the pilgrims at a median of 17 (1-45) days after their return from the Hajj and found 29 (17%) to be meningococcal carriers (P<0.001 compared with carriage rate before the Hajj) (table). Ninety five (56%) of returning pilgrims reported cough in the preceding month, and 70 (41%) reported use of antibiotics. Carriage was significantly higher in pilgrims who had not taken antibiotics (22/101, 22%) than in those who had taken antibiotics (7/70, 10%) (P=0.045), but no relation existed between carriage and age, sex, or recent symptoms of upperrespiratory tract infection.
Pulsed field gel electrophoresis showed 26/29 (90%) meningococcal isolates in Hajj returnees tobe a single clone, identified as serogroup W135 in most cases and related to the strains that caused Hajj associated invasive meningococcal disease in Singapore.
The returning pilgrims reported a median of 4 (1-10) people living in their household. The total number of contacts (non-Hajj pilgrims within the same household) was 317. We took swabs from 233(74%) of these household contacts at a median of 26 (3-45) days after the pilgrim's return to the household. The median age of household contacts was 20 (1-67) years, and 165 (52%) were children under the age of 18 years. The prevalence of meningococcal carriage in household contacts was 8.2%, of whom 42% were carrying the W135 clone (3.4% of all household contacts). All but one of the contacts carrying the W135 clone were contacts of returning pilgrims with the W135 clone. Of the 26 pilgrims carrying the W135 clone (all from different households), six (23%) transmitted this strainto seven contacts, of whom two were from the same household. The acquisition rate of the W135 clone in contacts of returning carriers of the same strain was 13% (seven out of 54 contacts).
A high acquisition rate of a single clone of W135 N meningitidis occurred during the 2001 Hajj pilgrimage. Many countries currently give bivalent meningococcal vaccine (covering A and C) to Hajj pilgrims. Vaccination with the quadrivalent meningococcal vaccine (also covering W135) should become mandatory for all Hajj pilgrims and be considered for their household contacts. Transmission of this clone from vaccinated Hajj returnees to their unvaccinated household contacts was substantial, putting contacts at particular risk of developing invasive disease. Our findings support a policy of administering antibiotics to pilgrims before their return to their countries of origin to eradicate carriage and thereby protect household contacts.
We thank Fatimah Karim and Anushia Panchalingham for taking swabs, Bernard Peperstraete for logistical help, Sindhu Ravindran for performing pulsed field gel electrophoresis, and Gamini Kumarsinghe for providing some of the meningococcal isolates of clinical cases. We also thank all the pilgrims and their contacts for participating in this study.
Contributors: AW-S had the idea for the study and was responsible for study design and for collection, analysis, and interpretation of data. TMSB was responsible for the meningococcal cultures, serogrouping, and pulsed field gel electrophoresis. AE was responsible for data entry and analysis. NIP contributed to the study design and data analysis and interpretation. All authors contributed to the final manuscript. AW-S is the guarantor.
Funding National Medical Research Council Singapore
Competing interests AW-S has been reimbursed by Glaxo SmithKline and Aventis for attending conferences. TMSB has been reimbursed by Oxoid, Bayer, and Bristol-Myers Squibb for attending conferences.